S
SciNeuro
Therapeutics for central nervous system neurodegenerative diseases
About SciNeuro
SciNeuro is a startup that is focused on transforming scientific discoveries into groundbreaking therapies for neurological diseases. The company operates in the neuroscience market, leveraging the latest scientific advancements to develop innovative treatments for brain diseases. Their target clients are individuals suffering from neurological conditions who are in need of effective therapies.
SciNeuro's business model is based on in-house discovery and development of new treatments, as well as collaborations with scientists globally. The company's revenue is likely generated through the development and commercialization of its therapeutic products.
The company is led by a team of experts with extensive experience in neurology and business development. Their strategic focus and deep expertise set them apart and fuel their unique pipeline of novel investigational medicines. The team's experience ranges from clinical development to regulatory strategy, patient advocacy, data-management, and biostatistics.
In addition, SciNeuro has a global reach and footprint, working with the best and brightest in the industry, united in the goal of having a dramatic impact on the treatment of CNS diseases.
In summary, SciNeuro is a promising startup in the neuroscience field, with a strong focus on developing innovative therapies for neurological diseases. Their collaborative approach and expert team position them well for success in this challenging and important area of medicine.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2020
- Headquarters
- Huangpu, China
- Employees
- 33
- Open positions
- None listed
- Dealroom signal
- 81.8/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Biotechnology, Neurology, Sustainable Development Goals, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANTOther financing | Dec 2025 | $5M | — | Michael J. Fox Foundation for Parkinson's Research | ↗ |
| EARLY VCOther financing | Dec 2025 | $53M | $500M | ARCH Venture Partners · Lilly Asia Ventures | ↗ |
Growth signals
Latest recorded traffic for SciNeuro is 2.5K monthly website visits, down 28.6% over the last three months. SciNeuro's team grew 3.1% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Michael J. Fox Foundation for Parkinson's Research
Series A5 investors entered at this stage
ARCH Venture Partners
Lilly Asia Ventures
Boyu Capital
General Atlantic
Sequoia
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about SciNeuro on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See SciNeuro’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.